TELO (Telomir Pharmaceuticals) Total Equity: $4.96 Mil (As of Mar. 2026)


TELO Telomir Pharmaceuticals Inc TELO
14 GF Score
Price $1.27
! 3 Warning Signs
View Full Analysis

What is Telomir Pharmaceuticals Total Equity?

Telomir Pharmaceuticals TELO -3.79% 14 Total Equity is $4.96 Mil as of Mar. 2026. GuruFocus rates TELO with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Telomir Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $4.96 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Telomir Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Telomir Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telomir Pharmaceuticals Total Equity Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
-0.14 -0.94 3.44 0.64 5.91

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 0.48 6.98 5.91 4.96
TELO
14GF Score
Telomir Pharmaceuticals Inc TELO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telomir Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Telomir Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7.341-1.428
=5.91

Telomir Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=5.79-0.827
=4.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $4.96 Mil mean?
Telomir Pharmaceuticals (TELO) has a Total Equity of $4.96 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Telomir Pharmaceuticals and its competitors.
Is Telomir Pharmaceuticals' Total Equity too high?
Telomir Pharmaceuticals' current Total Equity is $4.96 Mil. Overall, Telomir Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Telomir Pharmaceuticals' Total Equity compare to MAIA and LONA?
Telomir Pharmaceuticals' Total Equity of $4.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Telomir Pharmaceuticals and its competitors. Telomir Pharmaceuticals's current Total Equity is $4.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telomir Pharmaceuticals stock overvalued right now?
Telomir Pharmaceuticals (TELO) has a current Total Equity of $4.96 Mil. The current Total Equity is $4.96 Mil. Telomir Pharmaceuticals' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Telomir Pharmaceuticals (TELO), the current Total Equity is $4.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telomir Pharmaceuticals Business Description

Address 100 SE, 2nd Street, Suite 2000, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
14GF Score

Get the complete analysis for TELO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price